Imaging Center COE

The Additional Value of PET for MRI Guided Transrectal Prostate Biopsies - Morand Piert

Details
(Length of lecture - 12 minutes) In this presentation Dr. Piert discusses the random aspects of standard extended-sextant ultrasound-guided biopsy and the study that was designed to assess targeted vs standard biopsy and the 2 approaches combined for the diagnosis of intermediate- to high-risk prostate cancer. These trial results are published in JAMA, "Comparison of MR/ultrasound fusion-guided bi...

Ga-68 PSMA Lyophilized Ready to Use Kit for Diagnosis of Prostate Cancer by PET/CT - Stephan Maus

Details
(Length of lecture ~ 13 minutes) Stephan Maus discusses Ga-68 labeled prostate-specific membrane antigen (PSMA) whole body PET/CT scan cold kit for the detection of prostate cancer lesions. Specifically, cold kit procedures have been under intense investigation due to their shortened synthesis times, reduced error rates and eliminating expensive hardware, making it a reliable alternative. This pre...

What the Referring Clinician Needs to Know from Molecular Imaging in Prostate Cancer - Felix Feng

Details
(Length of lecture ~ 16 minutes) Dr. Feng provides a brief overview of prostate cancer management and how molecular imaging approaches can help guide the clinical management of prostate cancer, noting that imaging physicians need to educate their clinical colleagues about capabilities and limitations of these imaging studies. Additional content on molecular imaging ASCO 2017: How Advances in Molec...

18F-Fluciclovine: A New Option for Biochemical Recurrence in Prostate Cancer - Trond V. Bogsrud

Details
(Length of lecture ~ 15 minutes) Trond V. Bogsrud, MD presented "18F-Fluciclovine: A New Option for Biochemical Recurrence in Prostate Cancer” at the SNMMI 2016, detailing the uptake of fluciclovine (18F) as a PET imaging radiotracer in comparison to other PET tracers in patients with biochemically recurrent prostate cancer. Additional content on 18F - Fluciclovine Stepping Into the Light: "Radiol...

Using Fluciclovine in the Recurrent Prostate Cancer Patient- David Schuster

Details
Presentation from the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting. (Length of lecture 57 minutes) In this lecture, David Schuster describes the mechanisms of uptake of the PET radiotracer fluciclovine and identifies normal biodistribution of fluciclovine. In addition, Dr. Schuster discusses the FDA approval and clinical indication of fluciclovine and the clinical inter...

Biochemically Recurrent Prostate Cancer: Superior Agents to Conventional Imaging - Andrei Iagaru

Details
Dr. Andrei Iagaru states that the significantly changing landscape of prostate cancer diagnoses is due to new and improved imaging agents and access to resources that were once available only outside of the United State. In this particular study, 68 GA-RM2, formerly known as 68 Ga-Bombesin or BAY86-7548 PET/MRI was compared to conventional imaging for patients with biochemically recurring prostate...

PSMA PET/CT- Struggling with Increased Sensitivity

Details
Presentation from the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting. (Length of video ~ 23 minutes) Michael Hofman discusses PSMA as the new “gold standard” and how it is significantly superior to existing imaging modalities through case studies from the Peter MacCallum Cancer Centre and a review of abstracts. Related content: Systemic Radioligand Therapy with (177)Lu La...

Prostate Cancer and Molecular Tracers: 11C/18F-Choline for Biochemical Recurrence - Laura Evangelista

Details
(Length of lecture ~ 17 minutes) Laura Evangelista, MD PhD presented " Prostate Cancer and Molecular Tracers: 11C/18F-Choline for Biochemical Recurrence” at the SNMMI 2016, Dr. Evangelista details the best radiopharmaceutical agent: 11C/18F-Choline and the clinical role and ability to affect patient management and survival of prostate cancer. Additional content on Prostate Cancer and Molecular Tra...

Imaging in High Risk Prostate Cancer: Clinicians Perspective - Mark Frydenberg

Details
More from the 2017 APCCC (Advanced Prostate Cancer Consensus Conference): Read the 2017 APCCC Report on Management of Patients with Advanced Prostate Cancer Access to all Advanced Prostate Cancer Consensus Conference Video Coverage

Oligometastatic and Oligo-progressive Prostate Cancer: Answer of the Nuclear Specialist - Stefano Fanti

Details
Read the 2017 APCCC Report on Management of Patients with Advanced Prostate Cancer Access to all Advanced Prostate Cancer Consensus Conference Video Coverage Radiopharmaceuticals in Prostate Cancer - Stefano Fanti
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe